Clearmind Medicine Starts First Human Trial for CMND-100

Ticker: CMND · Form: 6-K · Filed: Mar 18, 2025 · CIK: 1892500

Clearmind Medicine INC. 6-K Filing Summary
FieldDetail
CompanyClearmind Medicine INC. (CMND)
Form Type6-K
Filed DateMar 18, 2025
Risk Levelmedium
Sentimentbullish

Sentiment: bullish

Topics: clinical-trial, drug-development, biotech

TL;DR

Clearmind Medicine just kicked off its first human trial for CMND-100 in alcohol use disorder patients. Big step!

AI Summary

Clearmind Medicine Inc. announced on March 18, 2025, the initiation of its first-in-human clinical trial for CMND-100, targeting patients with Alcohol Use Disorder. This marks a significant step in the company's development of novel treatments for psychiatric conditions.

Why It Matters

This trial represents a critical milestone for Clearmind Medicine, moving their potential treatment for Alcohol Use Disorder from preclinical to human testing, which could lead to new therapeutic options.

Risk Assessment

Risk Level: medium — Clinical trials are inherently risky, with a high probability of failure, and the success of CMND-100 is not guaranteed.

Key Players & Entities

FAQ

What is the primary purpose of the Form 6-K filing?

The Form 6-K filing incorporates by reference a press release issued by Clearmind Medicine Inc. on March 18, 2025, announcing the initiation of its first-in-human clinical trial for CMND-100.

What is the name of the drug candidate Clearmind Medicine is testing?

The drug candidate being tested is named CMND-100.

What medical condition is CMND-100 intended to treat?

CMND-100 is intended to treat Alcohol Use Disorder.

When was the press release announcing the clinical trial filed?

The press release was filed on March 18, 2025.

What type of clinical trial is this for CMND-100?

This is the first-in-human clinical trial for CMND-100.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on March 18, 2025 regarding Clearmind Medicine Inc. (CMND).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing